Northwest Biotherapeutics Inc - Notification that Annual Report will be submitted late (NT 10-K)
April 01 2008 - 6:02AM
Edgar (US Regulatory)
|
|
|
|
SEC FILE NUMBER
|
|
|
000-33393
|
|
|
|
|
|
CUSIP NUMBER
|
|
|
66737P 50 1
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
|
|
|
(Check one):
|
|
þ
Form 10-K
o
Form 20-F
o
Form 11-K
o
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
|
|
|
|
|
|
|
|
|
For Period Ended:
|
|
December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
|
|
|
|
|
For the Transition Period Ended:
|
|
|
|
|
|
|
|
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which
the notification relates:
PART I
REGISTRANT INFORMATION
Northwest Biotherapeutics, Inc.
Full Name of Registrant
Former Name if Applicable
7600 Wisconsin Avenue, Suite 750
Address of Principal Executive Office
(Street and Number)
City, State and Zip Code
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant
seeks relief pursuant to Rule 12b-25(b), the following should be completed. (
Check box if
appropriate
)
|
|
|
|
|
|
þ
|
|
|
(a)
|
|
The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense;
|
|
|
|
|
|
|
(b)
|
|
The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form
N-CSR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on
Form 10-Q or subject distribution report on Form 10-D, or
portion thereof, will be filed on or before the fifth
calendar day following the prescribed due date; and
|
|
|
|
|
|
|
|
(c)
|
|
The accountants statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
|
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR,
or the transition report portion thereof, could not be filed within the prescribed time period.
The registrant worked diligently to prepare its Annual Report on Form 10-K for its fiscal year
ended December 31, 2007. However, because of extensive business travel by key members of
management and the audit committee in an effort to expand the registrants European business
operations and seek additional funding sources, neither the registrants management nor the audit
committee of the registrants board of directors has had sufficient time to review and formally
approve the Form 10-K and financial statements included therein. In addition, the registrants
independent auditors have requested that the registrant provide additional confirmations in
connection with the audit of the registrants financial statements to be included in the Form 10-K,
which the registrant will be unable to provide prior to March 31, 2008. As a result of these
factors, the registrant was unable to complete such Annual Report on Form 10-K within the
prescribed time period without unreasonable effort or expense.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
Anthony P. Deasey
|
|
240
|
|
497-9024
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s).
þ
Yes
o
No
(3) Is it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings statements to be
included in the subject report or portion thereof?
o
Yes
þ
No
If so, attach an explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Northwest Biotherapeutics, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date:
|
|
March 31, 2008
|
|
By
|
|
/s/ ANTHONY P. DEASEY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anthony P. Deasey
|
|
|
|
|
|
|
Its:
Senior Vice President and Chief Financial Officer
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2023 to Jul 2024